AstraZeneca Pharma India Dirección
Dirección controles de criterios 1/4
Actualmente no disponemos de información suficiente sobre el CEO.
Información clave
Sanjeev Panchal
Chief Executive Officer (CEO)
₹21.1m
Compensación total
| Porcentaje del salario del CEO | 24.2% |
| Permanencia del CEO | 1.5yrs |
| Participación del CEO | n/a |
| Permanencia media de la dirección | less than a year |
| Promedio de permanencia en la Junta Directiva | 1.5yrs |
Actualizaciones recientes de la dirección
Recent updates
We Believe AstraZeneca Pharma India's (NSE:ASTRAZEN) Earnings Are A Poor Guide For Its Profitability
Jun 03
Why Investors Shouldn't Be Surprised By AstraZeneca Pharma India Limited's (NSE:ASTRAZEN) P/S
May 22We Ran A Stock Scan For Earnings Growth And AstraZeneca Pharma India (NSE:ASTRAZEN) Passed With Ease
Apr 04Is Now The Time To Put AstraZeneca Pharma India (NSE:ASTRAZEN) On Your Watchlist?
Nov 10AstraZeneca Pharma India's (NSE:ASTRAZEN) Dividend Will Be Increased To ₹16.00
Jul 06Is Now The Time To Put AstraZeneca Pharma India (NSE:ASTRAZEN) On Your Watchlist?
Jun 16Increases to CEO Compensation Might Be Put On Hold For Now at AstraZeneca Pharma India Limited (NSE:ASTRAZEN)
Aug 02Here's Why I Think AstraZeneca Pharma India (NSE:ASTRAZEN) Is An Interesting Stock
Feb 25Could The AstraZeneca Pharma India Limited (NSE:ASTRAZEN) Ownership Structure Tell Us Something Useful?
Feb 04Declining Stock and Solid Fundamentals: Is The Market Wrong About AstraZeneca Pharma India Limited (NSE:ASTRAZEN)?
Jan 18
Announcing: AstraZeneca Pharma India (NSE:ASTRAZEN) Stock Increased An Energizing 282% In The Last Five Years
Dec 31We're Not Counting On AstraZeneca Pharma India (NSE:ASTRAZEN) To Sustain Its Statutory Profitability
Dec 13Here's Why We Think AstraZeneca Pharma India (NSE:ASTRAZEN) Is Well Worth Watching
Nov 25Here's What We Think About AstraZeneca Pharma India's (NSE:ASTRAZEN) CEO Pay
Nov 07What Kind Of Investors Own Most Of AstraZeneca Pharma India Limited (NSE:ASTRAZEN)?
Oct 20AstraZeneca Pharma India Limited's (NSE:ASTRAZEN) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
Sep 24If You Had Bought AstraZeneca Pharma India (NSE:ASTRAZEN) Stock Three Years Ago, You Could Pocket A 298% Gain Today
Aug 28What Did AstraZeneca Pharma India's (NSE:ASTRAZEN) CEO Take Home Last Year?
Aug 02Could The AstraZeneca Pharma India Limited (NSE:ASTRAZEN) Ownership Structure Tell Us Something Useful?
Jul 12Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | ₹2b |
| Dec 31 2023 | n/a | n/a | ₹1b |
| Sep 30 2023 | n/a | n/a | ₹2b |
| Jun 30 2023 | n/a | n/a | ₹1b |
| Mar 31 2023 | ₹21m | ₹5m | ₹993m |
Compensación vs. Mercado: La compensación total de Sanjeev($USD253.13K) está por debajo de la media de empresas de tamaño similar en el mercado Indian ($USD444.28K).
Compensación vs. Ingresos: Datos insuficientes para comparar la compensación de Sanjeev con los resultados de la empresa.
CEO
Sanjeev Panchal (47 yo)
1.5yrs
Permanencia
₹21,149,014
Compensación
Dr. Sanjeev Kumar Panchal serves as Country President of AstraZeneca Pharma India Limited since January 01, 2023 and serves as its Managing Director since January 01, 2023. He serves as Director of AstraZe...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| MD, Country President & Director | 1.5yrs | ₹21.15m | sin datos | |
| Whole-Time Director & CFO | less than a year | sin datos | sin datos | |
| Legal Counsel | 7.4yrs | ₹3.73m | sin datos | |
| Company Secretary & Compliance Officer | 1.9yrs | sin datos | sin datos | |
| Vice President of Human Resources | no data | ₹12.28m | sin datos | |
| Interim Business Unit Head of Oncology & Director of Commercial Excellence | less than a year | sin datos | sin datos | |
| Head of Oncology Business Unit | less than a year | sin datos | sin datos | |
| Business Unit Head - Rare Disease unit | no data | sin datos | sin datos | |
| Finance Controller | no data | sin datos | sin datos |
1.0yrs
Permanencia media
Equipo directivo experimentado: El equipo directivo de ASTRAZEN no se considera experimentado ( 1.2 años antigüedad media), lo que sugiere un nuevo equipo.
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| MD, Country President & Director | 1.5yrs | ₹21.15m | sin datos | |
| Whole-Time Director & CFO | less than a year | sin datos | sin datos | |
| Independent Non-Executive Director | 7.6yrs | ₹1.20m | sin datos | |
| Independent Chairman of the Board | 11.6yrs | ₹1.40m | sin datos | |
| Additional Non-Executive Director | less than a year | sin datos | sin datos | |
| Independent Non-Executive Director | 2.6yrs | ₹1.30m | sin datos | |
| Non-Executive Director | less than a year | sin datos | sin datos |
1.5yrs
Permanencia media
58yo
Promedio de edad
Junta con experiencia: La junta directiva de ASTRAZEN no se considera experimentada (1.4 años de permanencia promedio), lo que sugiere una nueva junta directiva.